Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10498)	10/31/1997 2:51:00 PM
From: tdinovo	Read Replies (5) \| Respond to of 32384

Henry, CNN just posted a blurb on diabetes and its rapid rise in American and world populations. cnn.com Doesn't appear to be much new but more discussion in the general media should raise consciousness level regarding LLY:LGND deal. Ted

To: Henry Niman who wrote (10498)	10/31/1997 3:39:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Thanks for the continuing Ed on the SERMs!! >> I am fairly certain that they have a rather advanced and large Alzheimer program. << Never heard this before, Henry. Have you ever posted about a LGND Alzheimers program? Is Alzheimers considered a neurological disease? Never thought of LGND as being a neurological company before. Of course they are approaching it by a back door, so to speak. Is it safe to assume that the SERMs would only be useful for Alzheimers in women? Do you think their androgen program might be targetting a similar effect in men for Alzheimers? >>As you can imagine, the market is huge. However, since LGND has access to PFE, AHP, and LLY libraries, in addition to whatever their medicinal chemist come up with based on modification as active compounds, its easy to see why LGND would emerge as the leader in the area, and why more companies such as LLY would want to get in on the action.<< What exactly does access to these libraries give LGND? Anything they can use on their own? Or just what they can use with the company whose library they are accessing? Sounds like it would certainly enlarge the understanding of LGND chemists tremendously. Perhaps when you have a bit of time you might explain the implications of access to these libraries. I'm sure it is a very valuable resource, whose implications I don't understand very well.